Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (8,000,000)	$ (21,000,000)	$ (12,000,000)	$ (27,000,000)	$ (136,000,000)	$ (58,000,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization					121,000,000	137,000,000
Amortization of deferred costs and other assets					11,000,000	16,000,000
Impairment loss	0		0		54,000,000	0
Gain on casualty	(4,000,000)		(1,000,000)		(7,000,000)	(5,000,000)
Gain on sales of real estate					(59,000,000)	(16,000,000)
Equity-based compensation expense					8,000,000	9,000,000
Deferred tax benefit	(3,000,000)		1,000,000		(2,000,000)	0
Changes in assets and liabilities:
Accounts receivable					(6,000,000)	(6,000,000)
Other assets					4,000,000	7,000,000
Accounts payable and accrued expenses					(8,000,000)	6,000,000
Other liabilities					(1,000,000)	4,000,000
Net cash provided by (used in) operating activities					(21,000,000)	94,000,000
Cash flows from investing activities:
Capital expenditures, primarily investments in existing real estate					(18,000,000)	(61,000,000)
Lender and other escrows					(10,000,000)	0
Insurance proceeds related to real estate casualties					11,000,000	13,000,000
Proceeds from sales of real estate					205,000,000	86,000,000
Net cash provided by investing activities					188,000,000	38,000,000
Cash flows from financing activities:
Proceeds from debt					110,000,000	0
Repayment of debt					(164,000,000)	(62,000,000)
Debt issuance costs					(1,000,000)	0
Payment of insurance financing					(10,000,000)	(8,000,000)
Dividends on common stock					(22,000,000)	(35,000,000)
Distributions to noncontrolling interest					0	(1,000,000)
Purchase of common stock					0	(30,000,000)
Net cash used in financing activities					(87,000,000)	(136,000,000)
Increase (decrease) in cash, cash equivalents and restricted cash					80,000,000	(4,000,000)
Cash, cash equivalents and restricted cash at the beginning of the period		101,000,000		68,000,000	101,000,000	68,000,000	$ 68,000,000
Cash, cash equivalents and restricted cash at the end of the period	181,000,000		64,000,000		181,000,000	64,000,000	101,000,000
The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets to the amount shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents								$ 180,000,000	$ 101,000,000	$ 64,000,000
Restricted cash (included in other assets)								1,000,000		0
Total cash, cash equivalents and restricted cash	$ 181,000,000	$ 101,000,000	$ 64,000,000	$ 68,000,000	$ 181,000,000	$ 64,000,000	$ 68,000,000	$ 181,000,000	$ 101,000,000	$ 64,000,000